Massimiliano Mirabella

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6120032/publications.pdf

Version: 2024-02-01

210	7,357	53794	74163
papers	citations	45 h-index	75 g-index

215	215	215	9680
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
2	The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to lowâ€dose aspirin in patients with and without diabetes. Journal of Thrombosis and Haemostasis, 2012, 10, 1220-1230.	3.8	211
3	Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB Journal, 2007, 21, 1210-1226.	0.5	209
4	Enhanced Dystrophic Progression in mdx Mice by Exercise and Beneficial Effects of Taurine and Insulin-Like Growth Factor-1. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 453-463.	2.5	179
5	Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2015, 14, 985-991.	10.2	163
6	Coenzyme Q ₁₀ reverses pathological phenotype and reduces apoptosis in familial CoQ ₁₀ deficiency. Neurology, 2001, 57, 515-518.	1.1	157
7	pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. Journal of Neuroscience Research, 2006, 84, 1027-1036.	2.9	129
8	Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscular Disorders, 2004, 14, 130-135.	0.6	128
9	Î31- and Î32-Syntrophins, Two Novel Dystrophin-binding Proteins Localized in Neuronal Cells. Journal of Biological Chemistry, 2000, 275, 15851-15860.	3.4	117
10	Apoptosis in mitochondrial encephalomyopathies with mitochondrial DNA mutations: a potential pathogenic mechanism. Brain, 2000, 123, 93-104.	7.6	117
11	Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Annals of Neurology, 2004, 55, 195-206.	5.3	114
12	CD8+ T Cells in Facioscapulohumeral Muscular Dystrophy Patients with Inflammatory Features at Muscle MRI. Journal of Clinical Immunology, 2011, 31, 155-166.	3.8	113
13	Altered intestinal permeability in patients with relapsingâ€“remitting multiple sclerosis: A pilot study. Multiple Sclerosis Journal, 2017, 23, 442-446.	3.0	107
14	Different Molecular Signatures in Magnetic Resonance Imaging-Staged Facioscapulohumeral Muscular Dystrophy Muscles. PLoS ONE, 2012, 7, e38779.	2.5	106
15	Expression Profile of Long Non-Coding RNAs in Serum of Patients with Multiple Sclerosis. Journal of Molecular Neuroscience, 2016, 59, 18-23.	2.3	104
16	Difference in Expression of Phosphorylated Tau Epitopes between Sporadic Inclusion-body Myositis and Hereditary Inclusion-body Myopathies. Journal of Neuropathology and Experimental Neurology, 1996, 55, 774-786.	1.7	96
17	Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. Journal of Neuroimmunology, 2003, 139, 150-154.	2.3	94
18	Mutations in the 3â€² untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis. Human Molecular Genetics, 2013, 22, 4748-4755.	2.9	94

#	Article	IF	Citations
19	Magnetic resonance imaging pattern recognition in sporadic inclusionâ€body myositis. Muscle and Nerve, 2015, 52, 956-962.	2.2	93
20	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurology, The, 2019, 18, 834-844.	10.2	91
21	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 944-951.	1.9	88
22	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	3.7	86
23	Regulatory T cells fail to suppress CD4^{+â€ƒ}Tâ€bet⁺ T cells in relapsing multiple sclerosis patients. Immunology, 2009, 127, 418-428.	4.4	78
24	Neurotrophic Factors and Clinical Recovery in Relapsing-Remitting Multiple Sclerosis. Scandinavian Journal of Immunology, 2005, 62, 176-182.	2.7	77
25	MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16995-17000.	7.1	75
26	The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsingâ€“remitting multiple sclerosis. Journal of Neuroimmunology, 2007, 192, 174-183.	2.3	74
27	NCAM is hyposialylated in hereditary inclusion body myopathy due to GNE mutations. Neurology, 2006, 66, 755-758.	1.1	66
28	Ultrasound tissue characterization detectspreclinical myocardial structural changes inchildren affected by Duchenne muscular dystrophy. Journal of the American College of Cardiology, 2003, 42, 309-316.	2.8	65
29	Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscular Disorders, 2006, 16, 93-98.	0.6	64
30	Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis. Autoimmunity Highlights, 2014, 5, 77-85.	3.9	63
31	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	1.9	59
32	Apoptotic features accompany acute quadriplegic myopathy. Neurology, 2000, 55, 854-858.	1.1	58
33	Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clinical Immunology, 2006, 118, 77-82.	3.2	58
34	The ER-Bound RING Finger Protein 5 (RNF5/RMA1) Causes Degenerative Myopathy in Transgenic Mice and Is Deregulated in Inclusion Body Myositis. PLoS ONE, 2008, 3, e1609.	2.5	57
35	Muscle imaging findings in GNE myopathy. Journal of Neurology, 2012, 259, 1358-1365.	3.6	57
36	Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis. Annals of Neurology, 1996, 39, 389-391.	5.3	54

#	Article	IF	Citations
37	Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusionâ€body myopathy muscle. Journal of Neurochemistry, 2008, 105, 971-981.	3.9	53
38	IL17 and IFNÎ³ production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine, 2008, 44, 22-25.	3.2	53
39	NovelGNE mutations in Italian families with autosomal recessive hereditary inclusion-body myopathy. Human Mutation, 2004, 23, 632-632.	2.5	52
40	Personalized, bilateral whole-body somatosensory cortex stimulation to relieve fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1366-1374.	3.0	51
41	Apoptosis and ROS Detoxification Enzymes Correlate with Cytochrome c Oxidase Deficiency in Mitochondrial Encephalomyopathies. Molecular and Cellular Neurosciences, 2001, 17, 696-705.	2.2	50
42	Cervical cord dysfunction during neck flexion in Hirayamaâ€™s disease. Neurology, 2003, 60, 1980-1983.	1.1	49
43	Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma. Journal of Neuroimmunology, 2013, 263, 155-158.	2.3	49
44	Premature termination mutations in exon 3 of the SMN1 gene are associated with exon skipping and a relatively mild SMA phenotype. European Journal of Human Genetics, 2001, 9, 113-120.	2.8	48
45	Atrophy, Fibrosis, and Increased PAX7-Positive Cells in Pharyngeal Muscles of Oculopharyngeal Muscular Dystrophy Patients. Journal of Neuropathology and Experimental Neurology, 2013, 72, 234-243.	1.7	47
46	Ophthalmoplegia, demyelinating neuropathy, leukoencephalopathy, myopathy, and gastrointestinal dysfunction with multiple deletions of mitochondrial DNA: A mitochondrial multisystem disorder in search of a name. Muscle and Nerve, 1994, 17, 667-674.	2.2	46
47	Bridging the gap between vaccination with Bacille Calmette-GuÃ©rin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis. Current Opinion in Immunology, 2018, 55, 89-96.	5.5	45
48	Apolipoprotein E immunoreactive deposits in inclusion-body muscle diseases. Lancet, The, 1994, 343, 364-365.	13.7	44
49	Relapsing-remitting autoimmune agrypnia. Annals of Neurology, 2001, 50, 668-671.	5.3	44
50	An Italian family with inclusionâ€body myopathy and frontotemporal dementia due to mutation in the VCP gene. Muscle and Nerve, 2008, 37, 111-114.	2.2	44
51	Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies. Journal of Neurology, 2013, 260, 2396-2402.	3.6	44
52	Epstein-Barr virus genetic variants are associated with multiple sclerosis. Neurology, 2015, 84, 1362-1368.	1.1	44
53	Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naÃ¯ve patients with multiple sclerosis. Journal of Neurology, 2017, 264, 284-294.	3.6	44
54	Primary fibroblasts cultures reveal TDP-43 abnormalities in amyotrophic lateral sclerosis patients with and without SOD1 mutations. Neurobiology of Aging, 2015, 36, 2005.e5-2005.e13.	3.1	42

#	Article	IF	Citations
55	A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy. Neurology, 2019, 92, e2109-e2117.	1.1	40
56	Î±-Dystroglycan does not play a major pathogenic role in autosomal recessive hereditary inclusion-body myopathy. Neuromuscular Disorders, 2005, 15, 177-184.	0.6	39
57	Systematic assessment and characterization of chronic pain in multiple sclerosis patients. Neurological Sciences, 2018, 39, 445-453.	1.9	39
58	The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology. Frontiers in Immunology, 2019, 10, 1916.	4.8	39
59	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. Neurotherapeutics, 2020, 17, 200-207.	4.4	39
60	Idiopathic inflammatory myopathies. Current Opinion in Neurology, 1994, 7, 448-456.	3.6	38
61	Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies. Annals of Neurology, 1996, 40, 864-872.	5.3	37
62	Giant dystrophin deletion associated with congenital cataract and mild muscular dystrophy. Neurology, 1998, 51, 592-595.	1.1	37
63	Isolation and Characterization of Mesoangioblasts from Facioscapulohumeral Muscular Dystrophy Muscle Biopsies. Stem Cells, 2007, 25, 3173-3182.	3.2	37
64	Sleep and fatigue in multiple sclerosis: A questionnaire-based, cross-sectional, cohort study. Journal of the Neurological Sciences, 2017, 372, 387-392.	0.6	37
65	Sporadic late-onset nemaline myopathy: clinical, pathology and imaging findings in a single center cohort. Journal of Neurology, 2018, 265, 542-551.	3.6	36
66	Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis. Journal of Neurochemistry, 2006, 96, 777-789.	3.9	35
67	Increased aging in primary muscle cultures of sporadic inclusion-body myositis. Neurobiology of Aging, 2010, 31, 1205-1214.	3.1	35
68	Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems. Journal of Neurology, 2016, 263, 751-759.	3.6	35
69	Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study. CNS Drugs, 2018, 32, 963-970.	5.9	35
70	Fingolimod vs dimethyl fumarate in multiple sclerosis. Neurology, 2018, 91, e153-e161.	1.1	35
71	Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study. Neurotherapeutics, 2020, 17, 994-1004.	4.4	34
72	Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report. Multiple Sclerosis and Related Disorders, 2020, 44, 102323.	2.0	34

#	Article	IF	Citations
73	Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurological Sciences, 2011, 32, 841-847.	1.9	33
74	Hereditary inclusion-body myopathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 644-650.	3.8	33
75	Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of Myasthenia-Myositis association from a large cohort of patients. Autoimmunity Reviews, 2020, 19, 102498.	5.8	32
76	Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics, 2022, 19, 325-333.	4.4	32
77	Muscle <scp>MRI</scp> in female carriers of dystrophinopathy. European Journal of Neurology, 2012, 19, 1256-1260.	3.3	31
78	Leptin Enhances the Release of Cytokines by Peripheral Blood Mononuclear Cells from Relapsing Multiple Sclerosis Patients. Journal of Clinical Immunology, 2004, 24, 287-293.	3.8	30
79	TWEAK in Inclusion-Body Myositis Muscle. American Journal of Pathology, 2012, 180, 1603-1613.	3.8	30
80	Focal muscle vibration, an effective rehabilitative approach in severe gait impairment due to multiple sclerosis. Journal of the Neurological Sciences, 2017, 372, 33-39.	0.6	30
81	An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients. Frontiers in Neurology, 2020, 11, 564.	2.4	30
82	The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. CNS Drugs, 2021, 35, 861-880.	5.9	29
83	Analysis of NCAM helps identify unusual phenotypes of hereditary inclusion-body myopathy. Neurology, 2010, 75, 265-272.	1.1	28
84	DNA damage signatures in peripheral blood cells as biomarkers in prodromal huntington disease. Annals of Neurology, 2019, 85, 296-301.	5.3	28
85	An Italian family with autosomal recessive inclusion-body myopathy and mutations in the GNE gene. Neurology, 2002, 59, 1808-1809.	1.1	27
86	Chronic autoimmune autonomic neuropathy responsive to immunosuppressive therapy. Neurology, 2007, 68, 161-162.	1.1	27
87	Increased expression of T-bet in circulating B cells from a patient with multiple sclerosis and celiac disease. Human Immunology, 2008, 69, 837-839.	2.4	27
88	Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis. Journal of Neuroimmunology, 2013, 265, 124-127.	2.3	27
89	Hereditary inclusionâ€body myopathy: Clues on pathogenesis and possible therapy. Muscle and Nerve, 2009, 40, 340-349.	2.2	26
90	Mesoangioblasts from Facioscapulohumeral Muscular Dystrophy Display in Vivo a Variable Myogenic Ability Predictable by their in Vitro Behavior. Cell Transplantation, 2011, 20, 1299-1313.	2.5	26

#	Article	IF	Citations
91	Severe Disability in Patients with Relapsing-Remitting Multiple Sclerosis Is Associated with Profound Changes in the Regulation of Leptin Secretion. NeuroImmunoModulation, 2013, 20, 341-347.	1.8	26
92	Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clinical Immunology, 2007, 124, 284-293.	3.2	25
93	Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis. Neurology, 2021, 96, e1595-e1607.	1.1	25
94	Manifesting heterozygotes in McArdle's disease: clinical, morphological and biochemical studies in a family. Journal of the Neurological Sciences, 1993, 115, 91-94.	0.6	24
95	Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). PLoS ONE, 2017, 12, e0180651.	2.5	24
96	BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression. PLoS ONE, 2018, 13, e0206140.	2.5	24
97	Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients. Brain and Behavior, 2018, 8, e00968.	2.2	24
98	Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. Neurotherapeutics, 2021, 18, 1166-1174.	4.4	24
99	Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase. Acta Myologica, 2020, 39, 57-66.	1.5	24
100	Serum Levels of Anti-Myelin Antibodies in Relapsing-Remitting Multiple Sclerosis Patients during Different Phases of Disease Activity and Immunomodulatory Therapy. Disease Markers, 2005, 21, 49-55.	1.3	23
101	Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis. Cells, 2021, 10, 1146.	4.1	23
102	Clinical characteristics, course and prognosis of spinal multiple sclerosis. Spinal Cord, 2005, 43, 731-734.	1.9	22
103	The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis. Journal of Neuroimmunology, 2008, 205, 126-134.	2.3	22
104	The neurobiological underpinning of the social cognition impairments in patients with spinocerebellar ataxia type 2. Cortex, 2021, 138, 101-112.	2.4	22
105	Brainstem signs with progressing atrophy of medulla oblongata and upper cervical spinal cord. Lancet Neurology, The, 2007, 6, 562-570.	10.2	21
106	T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear cells during pregnancy correlates with post-partum activation of multiple sclerosis. Clinical Immunology, 2009, 131, 70-83.	3.2	21
107	Novel SEC61Gâ€“EGFR Fusion Gene in Pediatric Ependymomas Discovered by Clonal Expansion of Stem Cells in Absence of Exogenous Mitogens. Cancer Research, 2017, 77, 5860-5872.	0.9	21
108	Heterozygous KIF1A variants underlie a wide spectrum of neurodevelopmental and neurodegenerative disorders. Journal of Medical Genetics, 2021, 58, 475-483.	3.2	21

#	Article	IF	Citations
109	Apolipoprotein E alleles in sporadic inclusion-body myositis and hereditary inclusion-body myopathy. Annals of Neurology, 1996, 40, 264-264.	5.3	20
110	A human anti-neuronal autoantibody against GABAB receptor induces experimental autoimmune agrypnia. Experimental Neurology, 2007, 204, 808-818.	4.1	20
111	Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab. European Neurology, 2015, 73, 57-65.	1.4	20
112	Insulin-like Growth Factor I in Inclusion-Body Myositis and Human Muscle Cultures. Journal of Neuropathology and Experimental Neurology, 2004, 63, 650-659.	1.7	19
113	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. Journal of Neurology, 2020, 267, 3008-3020.	3.6	19
114	Skeletal muscle apoptosis is not increased in gastric cancer patients with mildâ€“moderate weight loss. International Journal of Biochemistry and Cell Biology, 2006, 38, 1561-1570.	2.8	18
115	Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. Journal of Neurology, 2021, 268, 2922-2932.	3.6	18
116	Evidence of involvement of leptin and IL-6 peptides in the action of interferon-beta in secondary progressive multiple sclerosis. Peptides, 2005, 26, 2289-2293.	2.4	17
117	Mosaic caveolin-3 expression in acquired rippling muscle disease without evidence of myasthenia gravis or acetylcholine receptor autoantibodies. Neuromuscular Disorders, 2011, 21, 194-203.	0.6	16
118	Pathogenic role of mtDNA duplications in mitochondrial diseases associated with mtDNA deletions. American Journal of Medical Genetics Part A, 2003, 118A, 247-254.	2.4	15
119	An Italian case of hereditary myopathy with early respiratory failure (HMERF) not associated with the titin kinase domain R279W mutation. Neuromuscular Disorders, 2010, 20, 730-734.	0.6	15
120	Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. Journal of Neurology, 2021, 268, 2238-2245.	3.6	15
121	Vessel-associated stem cells from skeletal muscle: From biology to future uses in cell therapy. World Journal of Stem Cells, 2010, 2, 39.	2.8	15
122	Analyzing the Effects of a G137V Mutation in the FXN Gene. Frontiers in Molecular Neuroscience, 2015, 8, 66.	2.9	14
123	Depression in multiple sclerosis: effect of brain derived neurotrophic factor Val66Met polymorphism and disease perception. European Journal of Neurology, 2016, 23, 630-640.	3.3	14
124	The cerebellar topography of attention sub-components in spinocerebellar ataxia type 2. Cortex, 2018, 108, 35-49.	2.4	14
125	Molecular Characterization of a Novel Endonuclease (Xib) and Possible Involvement in Lysosomal Glycogen Storage Disorders. Experimental and Molecular Pathology, 1999, 66, 123-130.	2.1	13
126	Sleep disordered breathing in a cohort of patients with sporadic inclusion body myositis. Clinical Neurophysiology, 2013, 124, 1615-1621.	1.5	13

#	Article	IF	Citations
127	The predictive value of CSF multiple assay in multiple sclerosis: A single center experience. Multiple Sclerosis and Related Disorders, 2019, 35, 176-181.	2.0	13
128	Oculopharyngeal muscular dystrophy: Clinical and neurophysiological features. Clinical Neurophysiology, 2015, 126, 2406-2408.	1.5	12
129	Cognitive and behavioral associated changes in manifest Huntington disease: A retrospective crossâ€sectional study. Brain and Behavior, 2021, 11, e02151.	2.2	12
130	Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients. Neurotherapeutics, 2021, 18, 2598-2607.	4.4	12
131	A TLR/CD44 axis regulates T cell trafficking in experimental and human multiple sclerosis. IScience, 2022, 25, 103763.	4.1	12
132	Shift of multiple sclerosis onset towards older age. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1137-1139.	1.9	12
133	Association study reveals novel risk loci for sporadic inclusion body myositis. European Journal of Neurology, 2017, 24, 572-577.	3.3	11
134	SativexÂ® effects on promoter methylation and on CNR1 / CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients. Journal of the Neurological Sciences, 2017, 379, 298-303.	0.6	11
135	Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results. Neurological Sciences, 2020, 42, 2837-2845.	1.9	11
136	A pilot study of lncRNAs expression profile in serum of progressive multiple sclerosis patients. European Review for Medical and Pharmacological Sciences, 2020, 24, 3267-3273.	0.7	11
137	An Italian family with autosomal recessive quadriceps-sparing inclusion-body myopathy (ARQS-IBM) linked to chromosome 9p1. Neurological Sciences, 2000, 21, 99-102.	1.9	10
138	IFN-Î² Therapy Regulates TLR7-Mediated Response in Plasmacytoid Dendritic Cells of Multiple Sclerosis Patients Influencing an Anti-Inflammatory Status. Journal of Interferon and Cytokine Research, 2015, 35, 668-681.	1.2	10
139	Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients. Journal of Neuroimmunology, 2018, 324, 165-171.	2.3	10
140	Abortion induces reactivation of inflammation in relapsing-remitting multipleÂsclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1272-1278.	1.9	10
141	Integrated Backscatter in Becker Muscular Dystrophy Patients With Functionally Normal Heart: Myocardial Ultrasound Tissue Characterization Study. Journal of the American College of Cardiology, 2006, 47, 686-688.	2.8	9
142	Progressive multifocal leukoencephalopathy in a patient with Franklin disease and hypogammaglobulinemia. Journal of the Neurological Sciences, 2009, 284, 203-204.	0.6	9
143	Novel homozygous GBA2 mutation in a patient with complicated spastic paraplegia. Clinical Neurology and Neurosurgery, 2018, 168, 60-63.	1.4	9
144	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. Journal of the Neurological Sciences, 2021, 424, 117385.	0.6	9

#	Article	IF	Citations
145	Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	9
146	Multi-organ investigation in 16 CADASIL families from central Italy sharing the same R1006C mutation. Neuroscience Letters, 2012, 506, 116-120.	2.1	8
147	Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients. Multiple Sclerosis and Related Disorders, 2020, 37, 101450.	2.0	8
148	Frataxin deficiency in Friedreichâ€™s ataxia is associated with reduced levels of HAX-1, a regulator of cardiomyocyte death and survival. Human Molecular Genetics, 2020, 29, 471-482.	2.9	8
149	Lower urinary tract disorders in multiple sclerosis patients: prevalence, clinical features, and response to treatments. Neurourology and Urodynamics, 2021, 40, 1500-1508.	1.5	8
150	Deletion Polymorphism of DNASE1L1, an X-Linked DNase I-like Gene, in Acid Maltase Deficiency Disorders. Experimental and Molecular Pathology, 2001, 70, 173-174.	2.1	7
151	Rituximab as a first-line treatment in pediatric neuromyelitis optica spectrum disorder. Neurological Sciences, 2015, 36, 2301-2302.	1.9	7
152	The influence of physiotherapy intervention on patients with multiple sclerosisâ€“related spasticity treated with nabiximols (THC:CBD oromucosal spray). PLoS ONE, 2019, 14, e0219670.	2.5	7
153	Genome-Wide Multiple Sclerosis Association Data and Coagulation. Frontiers in Neurology, 2019, 10, 95.	2.4	7
154	Cognitive Reserve in Early Manifest Huntington Disease Patients: Leisure Time Is Associated with Lower Cognitive and Functional Impairment. Journal of Personalized Medicine, 2022, 12, 36.	2.5	7
155	Coeliac disease presenting with acute disseminated encephalomyelitis. European Journal of Neurology, 2006, 13, 202-203.	3.3	6
156	Cerebellar degeneration and ocular myasthenia gravis in a patient with recurring ovarian carcinoma. Neurological Sciences, 2010, 31, 79-81.	1.9	6
157	A shared haplotype for dentatorubropallidoluysian atrophy (DRPLA) in Italian families testifies of the recent introduction of the mutation. Journal of Human Genetics, 2014, 59, 153-157.	2.3	6
158	Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 7, 68-69.	2.0	6
159	Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy. Neuroepidemiology, 2017, 48, 171-178.	2.3	6
160	Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod. Journal of the Neurological Sciences, 2019, 405, 116423.	0.6	6
161	Exit strategies for â€œneedle fatigueâ€• in multiple sclerosis: a propensity score-matched comparison study. Journal of Neurology, 2020, 267, 694-702.	3.6	6
162	In vivo Effects of Mitoxantrone on the Production of Pro- and Anti-Inflammatory Cytokines by Peripheral Blood Mononuclear Cells of Secondary Progressive Multiple Sclerosis Patients. NeuroImmunoModulation, 2006, 13, 76-81.	1.8	5

#	Article	IF	Citations
163	Huntington's disease and suicidal behavior: The importance of lithium treatment. Clinical Neurology and Neurosurgery, 2016, 145, 108-109.	1.4	5
164	Riluzole in patients with hereditary cerebellar ataxia â€“ Authors' reply. Lancet Neurology, The, 2016, 15, 789.	10.2	5
165	Low reliability of anti-KIR4.183â€“120 peptide auto-antibodies in multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 910-918.	3.0	5
166	Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. Frontiers in Neurology, 2019, 10, 695.	2.4	5
167	Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. Clinical Drug Investigation, 2020, 40, 319-326.	2.2	5
168	Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsingâ€“Remitting Multiple Sclerosis Treated With Dimethylfumarate. Frontiers in Neurology, 2021, 12, 683398.	2.4	5
169	Mixed connective tissue disease presenting as a peculiar myositis with poor muscle regeneration. Neurological Sciences, 2011, 32, 171-174.	1.9	4
170	Intravascular large B-cell lymphoma presenting as slowly progressive paraparesis with normal MRI features. Journal of the Neurological Sciences, 2012, 314, 171-174.	0.6	4
171	Rasmussen encephalitis: an unusual cause for intractable seizures in elderly. Neurological Sciences, 2014, 35, 143-145.	1.9	4
172	Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment. Multiple Sclerosis and Related Disorders, 2016, 9, 11-13.	2.0	4
173	An atypical case of acute disseminated encephalomyelitis associated with cytomegalovirus infection. Multiple Sclerosis and Related Disorders, 2016, 5, 70-72.	2.0	4
174	The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis. Neuroepidemiology, 2018, 50, 105-110.	2.3	4
175	Defining the disease course of TNFÎ± blockers-associated Multiple Sclerosis. Journal of Neuroimmunology, 2021, 353, 577525.	2.3	4
176	Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	4
177	Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. Journal of Neurology, 2022, 269, 1463-1469.	3.6	4
178	Update on Multiple Sclerosis Molecular Biomarkers to Monitor Treatment Effects. Journal of Personalized Medicine, 2022, 12, 549.	2.5	4
179	Treatment Challenges in Multiple Sclerosis â€“ A Continued Role for Glatiramer Acetate?. Frontiers in Neurology, 2022, 13, 844873.	2.4	4
180	Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?. Lancet Neurology, The, 2014, 13, 864.	10.2	3

#	Article	IF	Citations
181	Idiopathic inflammatory myopathies evaluated by near-infrared spectroscopy. Muscle and Nerve, 2015, 51, 830-837.	2.2	3
182	A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis. Neurological Sciences, 2021, 42, 1941-1947.	1.9	3
183	The drastic reduction of SMN protein in SMA I spinal cord motor neurons is not due to inefficient transcription. Neurogenetics, 1999, 2, 97-100.	1.4	2
184	Case of postpartum Parsonageâ€Turner syndrome. Muscle and Nerve, 2014, 49, 294-295.	2.2	2
185	Moving to Fingolimod From Natalizumab in Multiple Sclerosis: The ENIGM Is Not Solved. JAMA Neurology, 2014, 71, 924.	9.0	2
186	Acyclovir-related kidney injury during alemtuzumab infusion. Journal of Neurology, 2015, 262, 1772-1774.	3.6	2
187	A Case of Hemiabdominal Myoclonus. Clinical EEG and Neuroscience, 2015, 46, 331-334.	1.7	2
188	Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity. Journal of Endocrinological Investigation, 2020, 43, 1159-1161.	3.3	2
189	Comment on: Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110500.	3.5	2
190	Effects of rehabilitation treatment of the upper limb in multiple sclerosis patients and predictive value of neurophysiological measures. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 819-826.	2.2	2
191	Bilateral thoracic long nerve involvement in motor multifocal neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 584-584.	1.9	1
192	Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies. Clinical Neurophysiology, 2014, 125, 1925-1926.	1.5	1
193	Blepharoptosis onset after topical prostaglandin therapy for glaucoma. Clinical and Experimental Ophthalmology, 2015, 43, 689-690.	2.6	1
194	PLEC gene mutations cause familial disto-proximal myopathy and long QT syndrome mimicking mitochondrial disease. Neuromuscular Disorders, 2017, 27, S150-S151.	0.6	1
195	A unique case of multiphasic ADEM or what else?. Multiple Sclerosis and Related Disorders, 2019, 35, 73-75.	2.0	1
196	Different regimen of natalizumab treatment in multiple sclerosis patients: A real world study in Italy. Journal of the Neurological Sciences, 2019, 405, 338-339.	0.6	1
197	Hsa-miR223-3p circulating level is upregulated in Friedreichâ€™s ataxia and inversely associated with HCLS1 associated protein X-1, HAX-1. Human Molecular Genetics, 2022, , .	2.9	1
198	Hereditary Inclusion-Body Myopathies. , 2015, , 1145-1152.		0

#	Article	IF	Citations
199	D6â€…Dna damage in lymphocytes as a predictor of illness evolution in pre-manifest and overt huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A35.3-A36.	1.9	0
200	Response to the letter to the Editor for the manuscript â€œSleep and Fatigue in Multiple Sclerosis: A questionnaire-based, cross-sectional, cohort studyâ€•by Tomoyuki Kawada. Journal of the Neurological Sciences, 2017, 373, 142.	0.6	0
201	A phase 3 randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of sialic acid extended-release tablets in patients with GNE myopathy (GNEM). Neuromuscular Disorders, 2017, 27, S150.	0.6	0
202	Prevalence and severity of liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients. Journal of Hepatology, 2017, 66, S399-S400.	3.7	0
203	Sporadic inclusion body myositis: A polygenic disorder?. Neuromuscular Disorders, 2017, 27, S155.	0.6	0
204	Potential Effect of Cyclophosphamide on Bleb Survival in Five Patients with Multiple Sclerosis Who Underwent Glaucoma Surgery. Ophthalmology and Therapy, 2018, 7, 431-436.	2.3	0
205	P.20Expanding the myasthenia-myositis association spectrum: clinical, morphological and immunological data form a large case series. Neuromuscular Disorders, 2019, 29, S47.	0.6	0
206	F19â€…Cognitive reserve: the leisure time concurs to the cognition performance and to the independence of early huntington disease patients. , 2021, , .		0
207	CSF CXCL13 and chitinase 3-like-1 concentrations predict disease course in relapsing multiple sclerosis. Journal of the Neurological Sciences, 2021, 429, 118114.	0.6	0
208	A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-Î²1a in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2020, 40, 101952.	2.0	0
209	Hereditary inclusion-body myopathies. , 2020, , 479-489.		0
210	The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre. Journal of Personalized Medicine, 2022, 12, 591.	2.5	0